IOBT

IO Biotech, Inc.

1.27 USD
+0.04 (+3.25%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

IO Biotech, Inc. stock is down -7.97% since 30 days ago. The next earnings date is Aug 9, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 33.33% of the previous 2 June’s closed higher than May.

About IO Biotech, Inc.

IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating cancer therapies based on the T-win technology platform. The company's lead product candidate, IO102-IO103, is designed to target immunosuppressive proteins, such as Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1)